|
|
|
|
For patients who present with arterial vascular disease, there is no evidence that dipyridamole, in the presence or absence of another antiplatelet drug (chiefly aspirin) reduces the risk of vascular death, though it reduces the risk of further vascular events. This benefit is found only in patients presenting after cerebral ischemia. There is no evidence that dipyridamole alone is more efficacious than aspirin. |
|